• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.870 +0.190 (+11.31%)
Streaming Delayed Price Updated: 3:29 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,178,313
Open 1.690
Bid (Size) 1.860 (24,000)
Ask (Size) 1.870 (6,500)
Prev. Close 1.680
Today's Range 1.640 - 1.905
52wk Range 0.5137 - 1.950
Shares Outstanding 144,474,452
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss ↗
May 07, 2026
Via Chartmill
News headline image
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
May 07, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+64.0%
+64.0%
1 Month
+16.9%
+16.9%
3 Month
+58.5%
+58.5%
6 Month
+30.8%
+30.8%
1 Year
+173.0%
+173.0%

More News

Read More
News headline image
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
May 04, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
April 17, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Beats Q4 Estimates and Strengthens Cash Runway ↗
March 05, 2026
Via Chartmill
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends ↗
January 24, 2026
Via Chartmill
News headline image
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
March 24, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
March 23, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
March 11, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon (LXRX) Q4 2025 Earnings Call Transcript ↗
March 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
March 05, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
March 03, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
February 26, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
February 06, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
January 30, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Proposed Public Offering of Common Stock
January 29, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
January 23, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
January 21, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
January 09, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
December 31, 2025
Via Chartmill
News headline image
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
December 10, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
December 05, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?
Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market
What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?
The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.870
When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 05/08/26 03:29 PM ET
What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 270.17M
How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?
Lexicon Pharmaceuticals, Inc. - Common Stock has 270M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap